HRP20020429B8 - Polymorphic form of atorvastatin calcium - Google Patents

Polymorphic form of atorvastatin calcium

Info

Publication number
HRP20020429B8
HRP20020429B8 HR20020429A HRP20020429A HRP20020429B8 HR P20020429 B8 HRP20020429 B8 HR P20020429B8 HR 20020429 A HR20020429 A HR 20020429A HR P20020429 A HRP20020429 A HR P20020429A HR P20020429 B8 HRP20020429 B8 HR P20020429B8
Authority
HR
Croatia
Prior art keywords
atorvastatin calcium
polymorphic form
theta
peak
hydrate
Prior art date
Application number
HR20020429A
Other languages
English (en)
Croatian (hr)
Inventor
Ayalon Ari
Levinger Michal
Roytblat Sofia
Lifshitz Revital
Niddam Valerie
Aronhime Judith
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20020429A2 publication Critical patent/HRP20020429A2/xx
Publication of HRP20020429B1 publication Critical patent/HRP20020429B1/xx
Publication of HRP20020429B8 publication Critical patent/HRP20020429B8/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
HR20020429A 1999-11-17 2002-05-16 Polymorphic form of atorvastatin calcium HRP20020429B8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16615399P 1999-11-17 1999-11-17
PCT/US2000/031555 WO2001036384A1 (en) 1999-11-17 2000-11-16 Polymorphic form of atorvastatin calcium

Publications (3)

Publication Number Publication Date
HRP20020429A2 HRP20020429A2 (en) 2004-04-30
HRP20020429B1 HRP20020429B1 (en) 2006-05-31
HRP20020429B8 true HRP20020429B8 (en) 2007-03-31

Family

ID=22602039

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020429A HRP20020429B8 (en) 1999-11-17 2002-05-16 Polymorphic form of atorvastatin calcium

Country Status (20)

Country Link
EP (3) EP1235799B1 (pt)
JP (2) JP2003514798A (pt)
KR (1) KR20020063190A (pt)
CN (1) CN1423634A (pt)
AT (2) ATE478665T1 (pt)
AU (1) AU783002B2 (pt)
CA (1) CA2392096C (pt)
CZ (1) CZ20021642A3 (pt)
DE (2) DE60044884D1 (pt)
ES (2) ES2349364T3 (pt)
HR (1) HRP20020429B8 (pt)
HU (1) HUP0203257A3 (pt)
IL (2) IL149681A0 (pt)
PL (1) PL355805A1 (pt)
PT (2) PT1235799E (pt)
SI (2) SI1235799T1 (pt)
SK (1) SK286789B6 (pt)
WO (1) WO2001036384A1 (pt)
YU (1) YU35802A (pt)
ZA (1) ZA200203755B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002051804A1 (en) 2000-12-27 2002-07-04 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
CA2450111C (en) * 2001-06-29 2006-02-07 Warner-Lambert Company Llc Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EP1414796A1 (en) 2001-07-30 2004-05-06 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
MXPA04007939A (es) * 2002-02-15 2004-11-26 Teva Pharma Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix.
CN100379723C (zh) 2002-02-19 2008-04-09 特瓦制药工业有限公司 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
ES2315510T3 (es) * 2002-06-13 2009-04-01 Novartis Ag Sales de calcio de estatinas derivadas del indol.
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
DE202005020841U1 (de) 2004-09-28 2006-08-31 Teva Pharmaceutical Industries Ltd. Formen von Atorvastatin-Calcium, die im wesentlichen frei von Verunreinigungen sind
DE05810535T1 (de) 2004-10-18 2007-04-19 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von amorphem atorvastatin-hemi-calcium durch lösen des salzes in einem organischen lösungsmittel, bei dem es sich um eine mischung enes alkohols und eines ketons und/oder eines esters handelt, und entfernen des lösungsmittels
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
US20090208539A1 (en) 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
CA2499047A1 (en) 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
AU2006281229A1 (en) * 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
BRPI0614280A2 (pt) 2005-08-15 2009-08-04 Arrow Int Ltd atorvastatina sódica cristalina e amorfa
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
EP1808162A1 (en) 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
EP1923057A1 (en) 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
US8084488B2 (en) 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
EP1986997A4 (en) * 2006-02-22 2010-09-15 Matrix Lab Ltd NEW CRYSTALLINE HEMI-CALCIUM FORM OF ATORVASTATIN
KR101012917B1 (ko) * 2007-03-02 2011-02-08 동아제약주식회사 피롤 헵탄산 화합물의 신규한 결정형
EP2170841A1 (en) 2007-06-29 2010-04-07 Merck Generics (UK) Limited Process for introduction of hydroxyethoxy side chain in bosentan
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
CA2703230A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
US8785461B2 (en) 2008-02-08 2014-07-22 Generics [Uk] Limited Process for preparing bosentan
EP2350028A1 (en) 2008-11-03 2011-08-03 Generics [UK] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
EP2373609B1 (en) * 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN102249978A (zh) * 2011-06-09 2011-11-23 浙江金立源药业有限公司 阿托伐他汀钙的ky晶型及制备方法
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
PE20160945A1 (es) 2013-11-15 2016-09-26 Akebia Therapeutics Inc Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acetico, composiciones, y usos de las mismas
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN105085362B (zh) * 2015-09-18 2018-01-05 浙江海森药业有限公司 高纯度结晶型阿托伐他汀钙的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE178794T1 (de) * 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
PT1148049E (pt) * 1995-07-17 2005-02-28 Warner Lambert Co Formas cristalinas de hemi-sal de calcio do acido [r-(r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil)-1h-pirrole-1-heptanoico (atorvastatina)

Also Published As

Publication number Publication date
SI1235799T1 (en) 2005-06-30
CN1423634A (zh) 2003-06-11
DE60044884D1 (de) 2010-10-07
PL355805A1 (en) 2004-05-17
SK286789B6 (sk) 2009-05-07
YU35802A (sh) 2005-07-19
EP1535613B1 (en) 2010-08-25
EP1235799B1 (en) 2005-02-09
CA2392096C (en) 2008-07-15
ATE288893T1 (de) 2005-02-15
AU783002B2 (en) 2005-09-15
HRP20020429A2 (en) 2004-04-30
ZA200203755B (en) 2004-05-26
EP2206497A1 (en) 2010-07-14
SK6742002A3 (en) 2003-05-02
SI1535613T1 (sl) 2010-12-31
JP2003514798A (ja) 2003-04-22
HUP0203257A3 (en) 2003-05-28
AU1617301A (en) 2001-05-30
PT1235799E (pt) 2005-05-31
PT1535613E (pt) 2010-10-04
ES2349364T3 (es) 2010-12-30
EP1535613A3 (en) 2005-08-31
JP2009102439A (ja) 2009-05-14
HUP0203257A2 (hu) 2003-01-28
WO2001036384A1 (en) 2001-05-25
IL149681A (en) 2007-06-17
KR20020063190A (ko) 2002-08-01
HRP20020429B1 (en) 2006-05-31
ES2234699T3 (es) 2005-07-01
DE60018100D1 (en) 2005-03-17
CZ20021642A3 (cs) 2003-05-14
IL149681A0 (en) 2002-11-10
ATE478665T1 (de) 2010-09-15
DE60018100T2 (de) 2005-09-15
EP1535613A2 (en) 2005-06-01
EP1235799A4 (en) 2003-05-28
CA2392096A1 (en) 2001-05-25
EP1235799A1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
HRP20020429B8 (en) Polymorphic form of atorvastatin calcium
DE69908832T2 (de) Übertragung von Daten zur Übung musikalischer Aufführungen
ID24962A (id) Turunan-turunan sulfonamida sebagai bakal obat dari
DE69417464T2 (de) Chirurgisches laparoskopisches Instrument
NO20032758L (no) Krystallinske former av Atorvastatin
DE69316894D1 (de) Wiederverwendbares endoskopisches, chirurgisches instrument
DE60137039D1 (de) Verschiebung von verschlüssen zur herstellung von windeln
DE69918445D1 (de) Kalziumsalze enthaltende schweisshemmende zusammensetzungen
ITMI981811A0 (it) Pinza laparoscopica per sutura
BR9915515B1 (pt) composiÇço curÁvel de multicomponentes.
PT1414435E (pt) Composicao cristalina contendo escitalopram
DE69905054T2 (de) KRISTALLINE FORMEN VON EtO2C-CH2-(R)Cgl-Aze-Pab-OH
NO20023549D0 (no) Fremgangsmåte for rensing av 1,2-dikloretan
DE60126897D1 (de) Genaue Farbwiedergabe von Markenzeichenmustern
NO20035380D0 (no) Fremgangsmåte for dannelse av m degree nster
NO20023837L (no) Modulering av bendannelse
DE60235280D1 (de) Demodulation von mehrträgerphasenmodulierten signalen
IT1305003B1 (it) Punte per la perforazione del terreno con caratteristicheperfezionate per la rimozione dei detriti rocciosi prodotti e
DE69919049D1 (de) Herstellung von gefällten Kalziumkarbonatenthaltenden Produkten
ATE288909T1 (de) Indolderivate verwendbar zur behandlung von u.a. osteoporosis
NO983784D0 (no) FremgangsmÕter for fremstilling av bifenyl-isoksasolsulfonamider
DE60131049D1 (de) Vorverzerrung von Quadratursignalen
NO985809D0 (no) Modifisert form av R(-)-N-(4,4-di(3-metyltien-2-yl)but-3-enyl)-nipekotinsyrehydrokloridet
AU2003253593A8 (en) Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
ID27596A (id) Bentuk paroksetina kristal

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
B8IS Corrected front page of an hr-b document
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081115

Year of fee payment: 9

PBON Lapse due to non-payment of renewal fee

Effective date: 20091117